Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/22 CAR-T and Tislelizumab in R/R B-cell Non-Hodgkin's Lymphoma
NCT04539444Phase 2Completed
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19/22 CART (Soochow University) and tislelizumab in B-cell non-Hodgkin lymphoma (B-NHL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Overall Response Rate at 1 year and Progression-Free Survival at 1 year. Started Aug 2020; status: completed.
02
Drugs
CD19/22 CART (Soochow University)tislelizumab
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT04539444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539444.